| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PNAS..110E1500C |
| P356 | DOI | 10.1073/PNAS.1300616110 |
| P932 | PMC publication ID | 3631671 |
| P698 | PubMed publication ID | 23550156 |
| P5875 | ResearchGate publication ID | 236101168 |
| P50 | author | Carlo Maria Croce | Q640381 |
| P2093 | author name string | Thomas L Rothstein | |
| Nichol E Holodick | |||
| Franak Batliwalla | |||
| Shih-Shih Chen | |||
| Nicholas Chiorazzi | |||
| Sophia Yancopoulos | |||
| Xiao-Jie Yan | |||
| P2860 | cites work | Chronic lymphocytic leukemia | Q28236621 |
| Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling | Q28272891 | ||
| Characterization of autoantibodies against sulfatide from a V-gene phage-display library derived from patients with systemic lupus erythematosus. | Q31138438 | ||
| Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity | Q33771413 | ||
| Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia | Q33873337 | ||
| Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. | Q33873343 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression | Q34068006 | ||
| In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia | Q34078726 | ||
| The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 | ||
| B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia | Q34830865 | ||
| B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor | Q35077432 | ||
| Chronic lymphocytic leukemia: revelations from the B-cell receptor. | Q35667038 | ||
| Normal mouse peritoneum contains a large population of Ly-1+ (CD5) B cells that recognize phosphatidyl choline. Relationship to cells that secrete hemolytic antibody specific for autologous erythrocytes | Q36355168 | ||
| Abnormal transcription factor induction through the surface immunoglobulin M receptor of B-1 lymphocytes | Q36361454 | ||
| Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification. | Q36371091 | ||
| Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia | Q36399593 | ||
| IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions | Q36462397 | ||
| Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation | Q36972595 | ||
| Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells | Q37012514 | ||
| From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity | Q37012539 | ||
| Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression | Q37554072 | ||
| Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. | Q37910914 | ||
| The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 | ||
| Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. | Q39809953 | ||
| Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy | Q40010311 | ||
| A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies | Q40020213 | ||
| Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects | Q40743061 | ||
| Recognition of auto- and exoantigens by V4-34 gene encoded antibodies | Q40903369 | ||
| Structure and function of natural antibodies. | Q40948626 | ||
| Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration | Q42221150 | ||
| The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling | Q42475847 | ||
| The unique antigen receptor signaling phenotype of B-1 cells is influenced by locale but induced by antigen | Q42524573 | ||
| Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia | Q44189657 | ||
| Evaluation of DNA microarray results with quantitative gene expression platforms | Q46640412 | ||
| Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia | Q47290655 | ||
| In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow | Q49167019 | ||
| Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. | Q54580268 | ||
| Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution | Q58041607 | ||
| Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status | Q62028005 | ||
| Decreased surface IgM receptor-mediated activation of phospholipase Cγ2 in B-1 lymphocytes | Q71654233 | ||
| Identification of a precursor to phosphatidyl choline-specific B-1 cells suggesting that B-1 cells differentiate from splenic conventional B cells in vivo: cyclosporin A blocks differentiation to B-1 | Q73520522 | ||
| A VH11V kappa 9 B cell antigen receptor drives generation of CD5+ B cells both in vivo and in vitro | Q73709074 | ||
| Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues | Q73726012 | ||
| Peritoneal CD5+ B-1 cells have signaling properties similar to tolerant B cells | Q74314573 | ||
| Peritoneal and splenic B-1 cells are separable by phenotypic, functional, and transcriptomic characteristics | Q80350863 | ||
| Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival | Q80709731 | ||
| Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling | Q81299785 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | E1500-7 | |
| P577 | publication date | 2013-04-02 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling | |
| P478 | volume | 110 |
| Q39877099 | A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells |
| Q37235687 | A role for IRF4 in the development of CLL. |
| Q91141597 | An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies |
| Q36799197 | BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia |
| Q34039406 | Bruton's tyrosine kinase (BTK) inhibitors in clinical trials |
| Q42700845 | Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling |
| Q46074725 | Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. |
| Q40369611 | Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo |
| Q35692395 | Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. |
| Q41012392 | Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia |
| Q57110641 | Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency |
| Q35377918 | Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia |
| Q46329563 | Inhibition of reactive oxygen species limits expansion of chronic lymphocytic leukemia cells |
| Q47120488 | Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. |
| Q26782633 | PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL) |
| Q47445525 | Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q36867755 | Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade |
| Q49888075 | Role of Bruton's tyrosine kinase in B cells and malignancies |
| Q26773053 | TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia |
| Q35861964 | TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells |
| Q35153215 | Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. |
Search more.